CAMBRIDGE, Mass., Jan. 31, 2018 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company
focused on the development of curative therapeutics using CRISPR/Cas9 technology, will present or host one-on-one meetings at the
following upcoming healthcare conferences in February:
Wednesday, February 14, 2018
Leerink Partners 7th Annual Healthcare Conference
Who: Tom Barnes, Ph.D., Senior Vice President, Innovation Sciences
Location: New York, New York
Presentation Time: 1:00pm EST
Tuesday, February 27, 2018
Credit Suisse 2018 Global Healthcare Conference
Who: Tom Barnes, Ph.D., Senior Vice President, Innovation Sciences
Location: London, United Kingdom
One-on-one meetings only
A live webcast of Intellia’s presentations will be accessible through the Events and Presentations page of the Investor Relations
section of the company’s website at www.intelliatx.com. To access the webcasts, please log on to the Intellia website approximately
15 minutes prior to the start time to ensure adequate time for any software downloads that may be required. A replay of the webcast
will be available on Intellia’s website for 14 days following each conference.
About Intellia Therapeutics
Intellia Therapeutics is a leading genome editing company focused on the development of proprietary, curative therapeutics using
the CRISPR/Cas9 system. Intellia believes the CRISPR/Cas9 technology has the potential to transform medicine by permanently editing
disease-associated genes in the human body with a single treatment course. The combination of deep scientific, technical and
clinical development experience, along with its leading intellectual property portfolio, puts Intellia in a unique position to
unlock broad therapeutic applications of the CRISPR/Cas9 technology and create a new class of therapeutic products. Learn more
about Intellia Therapeutics and CRISPR/Cas9 at intelliatx.com; Follow us on Twitter @intelliatweets
